Document:

Exhibit 10.31

 

Stock
Purchase Agreement

 

THIS STOCK
PURCHASE AGREEMENT (the “Agreement”) is made and entered on December 20, 2019 by and among, Orchestra BioMed, Inc.,
a Delaware corporation (“Purchaser”), Orchestra Medical Ventures, LLC (“Seller”) and Accelerated
Technologies, Inc., a Delaware corporation (the “Company”).

 

WHEREAS, Seller
owns all of the shares of the common stock of the Company at $0.01 par value (the “Shares”), and Purchaser desires
to purchase the Shares, subject to the terms and subject to the conditions hereinafter set forth;

 

WHEREAS, prior
to the Transaction, the Company was the owner of 2,974 shares of Series A Preferred Stock, par value $0.0001 per share, of Purchaser,
which such shares were, immediately prior to the Transaction, distributed to Seller; and

 

WHEREAS, prior
to the Transaction, the Company was the owner of 272,000 shares of Series B Redeemable Convertible Preference Shares of EUR € 0.001
each of Vivasure Medical Limited, an Ireland limited company, which such shares were, immediately prior to the Transaction, distributed
to Paul Teirstein, an individual.

 

NOW, THEREFORE,
in consideration of the foregoing, and the representations, warranties, covenants and conditions set forth in this Agreement, the parties
hereto, intending to be legally bound, hereby agree as follows:

 

1.
Purchase and Sale. Subject to the terms and conditions hereinafter set forth, Seller hereby agrees to sell and the Purchaser agrees
to purchase from Seller the Shares in exchange for the consideration set forth in Section 2 of this Agreement (the “Transaction”).
Following the closing, Seller shall sell, convey, transfer, and, if applicable, deliver to the Purchaser certificates representing the
Shares which shall be duly endorsed for transfer or accompanied by appropriate stock transfer powers duly executed in blank, in either
case with signatures guaranteed in the customary fashion, and shall have all the necessary documentary transfer tax stamps affixed thereto
at the expense of the Company. 

 

2.
Consideration. 

 

		(a)	Series A Preferred Stock
of Purchaser. As total consideration for the purchase and sale of the Shares, Purchaser shall issue to the Seller 11,639 shares of
Series A Preferred Stock, par value $0.0001 per share, of Purchaser, valued at $15.00 per share (such shares, the “Purchaser
Shares”).

 

		(b)	Calculation of Number
of Purchaser Shares. The value of the Shares to be purchased by the Purchaser, and the number of Purchaser Shares payable to Seller
pursuant to Section 2(a) above, is based on the average closing price per share of the common stock of Motus GI Holdings, Inc.
(“Motus”), which such shares are listed on the NASDAQ Capital Market and 51,498
of which such shares are owned by the Company, which such average closing price per share, based on the fifteen (15) days prior to and
the fifteen (15) days after the pricing of Motus’ underwritten registered public offering of 6,666,667 shares of its common stock
at a price to the public of $3.00 per share, announced on June 26, 2019, was equal to $3.39.

 

    1

     

    

 

3.
Representations and Warranties of Sellers. The Seller hereby warrants and represents:

 

		(a)	Organization and Standing.
The Seller is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware
and has the power and authority to carry on its business as it is now being conducted.

 

		(b)	Authority. The Seller
has all requisite power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. This Agreement has been duly executed and delivered by the Seller and (assuming due authorization, execution and
delivery by the Seller) this Agreement constitutes a legal, valid and binding obligation of the Seller enforceable against the Seller
in accordance with its terms.

 

		(c)	Nonaffiliated Status.
Seller acknowledges that Seller may be an “affiliate” of the Company as that term is defined in paragraph (a)(1) of Rule
144 promulgated by the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”).

 

		(d)	Beneficial Ownership;
Private Transaction. Seller acquired the Shares and Seller has beneficially owned the Shares continuously since that time until the
date hereof. The Shares were originally acquired by Seller in a private transaction separate from any public offering, and Seller did
not purchase such Shares with a view to distribution in violation of the Securities Act.

 

		(e)	No Additional Offers;
No Solicitation. Seller has made no offers to sell the Shares to any party other than the Purchaser. Seller has not offered or sold
the Shares by any form of general solicitation or advertising.

 

		(f)	Title. Seller has
good title to, and is the sole record owner of, the Shares, free of any and all liens, pledges, encumbrances, security interests, restrictions
on transfer and rights of Seller and of any third parties (any of the foregoing individually a “Lien”
and collectively “Liens”), other than in each case (i) restrictions on transfer
and other restrictions under applicable state and federal securities laws and (ii) Liens imposed upon the Company. The Shares to be sold
by Seller hereunder constitute all Shares of the Company legally or beneficially owned or held by Seller or its affiliates, and upon
consummation of the Closing, neither Seller nor its affiliates shall have any other rights by contract, option or otherwise to acquire
any equity securities of the Company.

 

		(g)	Restrictions on Stock.
The Seller has the sole voting power and sole power of disposition with respect to all of the Shares with no limitations, qualifications
or restrictions on such rights and powers. The Shares will be transferred to Purchaser pursuant to this Agreement free and clear of any
liens, security interests, claims, mortgages, deeds of trust, preemptive rights, leases, charges, options, rights of first refusal, easements,
proxies, voting trusts or agreements, transfer restrictions, pledges, assessments, covenants, burdens and other encumbrances of every
kind, including restrictions on voting or use. The Seller is not subject to any agreements, arrangements, options, warrants, calls, rights,
commitments or other restrictions relating to the sale, transfer, purchase, redemption or voting of the Shares.

 

    2

     

    

 

4.
Representations and Warranties of the Company. 

 

		(a)	Organization and Standing.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the
corporate power and authority to carry on its business as it is now being conducted.

 

		(b)	Authority. The Company
has all requisite power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. This Agreement has been duly executed and delivered by the Company and (assuming due authorization, execution and
delivery by the Company) this Agreement constitutes a legal, valid and binding obligation of the Company enforceable against the Company
in accordance with its terms.

 

		(c)	Share Issuance. All
of the Shares have been duly authorized, are validly issued and are non-assessable.

 

5. Representations
and Warranties of Purchaser. 

 

		(a)	Organization and Standing.
Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the
corporate power and authority to carry on its business as it is now being conducted.

 

		(b)	Authority. Purchaser
has all requisite power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. This Agreement has been duly executed and delivered by Purchaser and (assuming due authorization, execution and
delivery by Purchaser) this Agreement constitutes a legal, valid and binding obligation of Purchaser enforceable against Purchaser in
accordance with its terms.

 

6. Further
Assurances. Following the closing, each of the parties hereto shall execute and deliver such additional documents, instruments, conveyances
and assurances, and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the
transactions contemplated by this Agreement.

 

7.
General Provisions.

 

		(a)	Entire Agreement.
This Agreement (including any written amendments hereof executed by the parties) constitutes the entire Agreement and supersedes all
prior agreements and understandings, oral and written, between the parties hereto with respect to the subject matter hereof.

 

    3

     

    

 

		(b)	Sections and Other Headings.
The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation
of this Agreement.

 

		(c)	Successors and Assigns. This Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

		(d)	Amendment; Waiver.
This Agreement may be amended, modified or waived only by the written agreement of Purchaser and the Seller. No failure or delay of any
party to exercise any right or remedy given to such party under this Agreement or otherwise available to such party or to insist upon
strict compliance by any other party with its obligations hereunder, no single or partial exercise of any such right or power, or any
abandonment or discontinuance of steps to enforce such right or power, and no custom or practice of the parties in variance with the
terms hereof, shall constitute a waiver of any party’s right to demand exact compliance with the terms hereof. Any written waiver
shall be limited to those items specifically waived therein and shall not be deemed to waive any future breaches or violations or other
non-specified breaches or violations unless, and to the extent, expressly set forth therein.

 

		(e)	Notices. All notices
and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the
earlier of actual receipt, or (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail
or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (iv) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next business day delivery, with written verification of receipt. Such communications must be sent to the addresses set forth next to
such party’s signature to this Agreement.

 

		(f)	Counterparts. This
Agreement may be executed in any number of counterparts, all of which will be one and the same agreement. This Agreement will become
effective when each party to this Agreement will have received counterparts signed by all of the other parties. Facsimile copies of signed
signature pages will be deemed binding originals.

 

		(g)	Governing Law. This
Agreement and all transactions contemplated hereby, shall be governed by, construed and enforced in accordance with the laws of the State
of Delaware.

 

The remainder of this page is intentionally
blank.

 

    4

     

    

 

IN WITNESS
WHEREOF, this Agreement has been executed by each of the individual parties hereto on the date first above written.

 

	 	THE COMPANY:
	 	 
	 	Accelerated Technologies, Inc.
	 	 
	 	/s/ David Hochman
	 	By:	 David Hochman
	 	Its:	Sole Director

 

	 	Address: 	150 Union Square Drive,
	 	 	New Hope, PA 18938

 

	 	PURCHASER:
	 	 
	 	Orchestra BioMed, Inc.
	 	 
	 	/s/ David Hochman
	 	By:	David Hochman
	 	Its:	Chief Executive Officer

 

	 	Address: 	150 Union Square Drive,
	 	 	New Hope, PA 18938

 

	 	SELLER:
	 	 
	 	Orchestra Medical Ventures, LLC
	 	 
	 	/s/ David Hochman
	 	By:	David Hochman
	 	Its:	Managing Partner

 

	 	Address: 	150 Union Square Drive,
	 	 	New Hope, PA 18938

 

 

5Exhibit
10.1

 

EMPLOYMENT
AGREEMENT

 

This
Employment Agreement (the “Agreement”) is made as of October 3, 2022 by and between Biofrontera, Inc, a Delaware corporation
(the “Company”) having its registered office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and Fred Leffler (the “Executive”).

 

BACKGROUND
INFORMATION

 

The
Company wishes to secure the employment services of the Executive for an indefinite period of time and upon the particular terms and
conditions hereinafter set forth. The Executive is willing to be so employed. Accordingly, the parties agree as follows:

 

OPERATIVE
PROVISIONS

 

	1.	EMPLOYMENT
                                            ANDTERM

 

The
Company proposes to employ the Executive in the capacity of “Chief Financial Officer”. It is agreed that the Executive will
devote 100% of their working capacity to the performance of their duties hereunder and will directly report to the Chief Executive Officer.
This Agreement shall remain in full force and effect for an indefinite period of time and is subject to termination pursuant to Section
9 of the Agreement.

 

	2.	DUTIES

 

During
the term of the Agreement, whether initial or extended, the Executive shall render to the Company services as Chief Financial Officer
of the Company and shall perform such duties as may be designated by and subject to the supervision of the Chief Executive Officer, and
shall serve in such additional capacities appropriate to his responsibilities and skills as shall be designated by the Chief Executive
Officer. During such period, the Executive shall devote their full attention, time and energies as necessary to the business affairs
of the Company (subject to the terms of Section 1 above and Section 5 below) and will use reasonable business efforts to promote the
interests and reputation of the Company. Executive may only pursue non-competitive activities as do not interfere with the complete performance
of their obligations hereunder unless by prior agreed of the Company’s Chief Executive Officer.

 

	3.	LOCATION
                                            OF EMPLOYMENT

 

Executive’s
principal place of employment shall be at the Company’s headquarters, which is currently located in Woburn, MA. Executive shall
also be required to conduct reasonable business travel as directed by the Chief Executive Officer and consistent with the Executive’s
duties and responsibilities.

 

    	1

    	 

    

 

	4.	COMPENSATION

 

For
the services to be rendered by the Executive under the Agreement, the Company shall pay a salary while Executive is rendering such services
and performing their duties hereunder, and the Executive shall accept such salary as full payment for such service. The annual base salary
will be $355,000.00 reduced by (i) Federal income tax withholding, (ii) FICA; and (iii) such other reductions as may be agreed upon by
the parties or required by law. The salary shall be paid in bi-weekly installments and in accordance with the Company’s customary
payroll procedure.

 

In
addition, Company shall pay to Executive a one-time signing bonus of $25,000.00 (subject to applicable tax withholdings). This sum shall
be paid to Executive at the time of Executive receives their first regularly scheduled paycheck.

 

For
each fiscal year in effect during the active life of this Agreement, the Executive shall be eligible to receive a cash bonus of up to
40% of their base salary (the “Target Bonus”) upon the attainment of performance goals set in advance by the Chief Executive
Officer. During Executive’s first calendar year of employment, the Target Bonus shall be prorated based on the time Executive was
actively employed by the Company during calendar year. All Target Bonuses shall be paid after the completion of the Company’s financial
statements for the applicable fiscal year as and when bonuses are paid to members of senior management generally. The actual amount of
Executive’s bonus shall depend upon the level of achievement of set targets, however no bonus shall be paid if the level of target
achievement is below 70%.

 

Executive
shall be eligible to participate in Company’s stock option plan. The number of options awarded to Executive shall be at the discretion
of the Board of Directors. At the time of hire, Executive shall receive 100,000 stock options, which shall be subject to same vesting
scheudule and other terms, conditions, and restrictions imposed upon all awards made given under Company’s employee stock option
program.

 

Upon
the Executive’s termination of employment, regardless of the reason for such termination and regardless of the party by whom such
termination is initiated, the Executive shall be entitled to immediate payment of all accrued but unpaid base salary and expenses owed.

 

In
addition, upon the Executive’s termination of employment either (i) by the Company for any reason other than termination for “Cause”
(under Section 9(d) of the Agreement) or (ii) by Executive for “Good Reason” (under Section 9(g)), the Executive shall be
entitled to receive a severance payment equal to one twelfth the Executive’s then-current annual base salary for each full year
the Executive has been employed by the Company; provided, however, that such payment (a) shall not be less than six (6) months of Executive’s
then-current base salary, and (b) shall not exceed two (2) full years of Executive’s then-current base salary. Such severance payments
shall be expressly conditioned upon the Executive’s execution and delivery to the Company of a waiver and release of claims in
a form reasonably acceptable to the Company (the “Release”) and such Release becoming irrevocable no later than sixty (60)
days following Executive’s termination of employment. For the avoidance of doubt, the payments and benefits set forth in this paragraph
shall be forfeited if such Release has not been executed, delivered and become irrevocable within such sixty (60) day period.

 

    	2

    	 

    

 

	5.	VACATION;
                                            FRINGE BENEFITS; REIMBURSEMENT OF EXPENSES

 

The
Executive shall be entitled to paid time off in accordance with the Company’s standard policy. Executive shall not be entitled
to receive monetary or other valuable consideration for vacation time which is accrued but not taken, unless so ordered by the Board
of Directors. Timing of vacations shall be reasonably exercised by the Executive.

 

During
their period of employment hereunder, the Executive shall further be entitled to (a) such leave by reason of physical or mental disability
or incapacity and to such participation in medical and life insurance, pension benefits, disability and other fringe benefit plans as
the Company may make generally available to all of its other employees from time to time; subject, however, as to such plans, to such
budgetary constraints or other limitations as may be imposed by the Board of Directors of the Company from time to time; and (b) reimbursement
for all normal and reasonable expenses necessarily incurred by their in the performance of their obligations hereunder, subject to such
reasonable substantiation requirements as may be imposed by the Company to all employees of the Company, unless otherwise agreed to by
the Board of Directors.

 

	6.	CONFIDENTIAL
                                            INFORMATION AND PROPRIETARY INTERESTS

 

Executive
acknowledges that as Chief Financial Officer, they will receive Company’s Confidential Information. Executive recognizes that all
such Confidential Information is and shall remain the sole property of the Company, free of any rights of Executive, and acknowledges
that the Company has a vested interest in assuring that all such Confidential Information remains secret and confidential. Therefore,
Executive agrees that during or after the expiration of their term of employment with the Company, the Executive shall not communicate
or divulge to, or use for the benefit of, any individual, association, partnership, trust, corporation or other entity except the Company,
any Confidential Information received by the Executive by virtue of their employment, without first being in receipt of the Company’s
written consent to do so.

 

For
the purposes of this Agreement, the term “Confidential Information” means:

 

	a.	All
    information developed or used by the Company or its associates relating to business operations, including but not limited to customer
    lists, purchase orders, supplier or distributor information, financial data, pricing information and price lists, business plans,
    marketing strategies, personnel records, and all books, records, manuals, advertising materials, catalogues, correspondences, mailing
    lists, production data, and purchasing materials; and
	 	 
	b.	All
    proprietary information of the company (or any records related to the same), including but not limited to all trade secrets, inventions,
    processes, procedures, research records, market surveys or marketing know-how, trademarks, copyrights, patents, and patent applications.
	 	 
	c.	All
    information of the Company disclosed during the course of activities performed on behalf of the Board of Directors including discussions,
    votes, or other information whether publicly disclosed or not.

 

The
term “Confidential Information” shall not include information that is or becomes generally known to the public other than
as a result of a disclosure by Executive in violation of this Agreement, or by any other employee of the Company subject to confidentiality
obligations.

 

    	3

    	 

    

 

	7.	NON-COMPETITION/NON-SOLICITATION

 

During
the term of their employment hereunder and for a period of one (1) year following the earlier of (i) either party’s notice of termination
under Section 9(b), or (ii) the actual termination hereof for any reason other than (a) the Company’s discontinuance of activities;
or (b) an adjudication of the Company’s material breach of any of its obligations set forth in Sections 1, 2, 4, and 5 inclusive,
the “Restricted Period”), the Executive shall not, without prior written consent by the Board of Directors of the Company,
directly or indirectly, engage in or become an owner of, render any service to, enter the employment of, or represent or solicit for
any business which competes with any activity of the Company conducted at any time during the Executive’s period of employment
and which is located in the United States. The parties expressly agree that the duration and geographical area of the restrictive covenant
are reasonable.

 

The
covenant shall be construed as an agreement independent of any other provision herein; and the existence of any claim or cause of action
of the Executive against the Company regardless of how arising, shall not constitute a defense to the enforcement by the Company or its
terms. If any portion of the covenant is held by a court to be unenforceable with respect either to its duration or geographical area,
for whatever reason, it shall be considered divisible both as to time and geographical area, resulting in an intended requirement that
the longest lesser period of time or largest lesser geographical area found by such court to be a reasonable restriction shall remain
an effective restrictive covenant, specifically enforceable against the Executive.

 

Notwithstanding
any statement contained in this Section to the contrary, legal or beneficial ownership by the Executive of a less than five percent (5%)
interest in a competitive corporation the stock of which is publicly traded on a stock exchange or by means of an electronic dealer quotation
system, shall not of itself be deemed to constitute a breach by the Executive of the terms hereof.

 

Additionally,
during the Executive’s employment with the Company and thereafter during the Restricted Period, the Executive shall not, and shall
not permit any third party subject to Executive’s direction or control to, directly or indirectly, (i) call upon, accept business
from, or solicit the business of any Person who is, or who had been at any time during the preceding twelve months, a customer or supplier
of the Company, (ii) otherwise divert or attempt to divert any business from the Company, (iii) interfere with the business relationships
between the Company and any of its customers, suppliers or others with whom they have business relationships or (iv) recruit or otherwise
solicit or induce, or enter into or participate in any plan or arrangement to cause, any Person who is an employee of, or otherwise performing
services for, the Company to terminate their employment or other relationship with the Company, or hire any Person who bas left the employ
of or ceased providing services to the Company during the Restricted Period.

 

    	4

    	 

    

 

	8.	REMEDIES
                                            FOR BREACH OF EXECUTIVE OBLIGATIONS

 

The
parties to the agreement agree that the services of the Executive are of a personal, specific, unique and extraordinary character and
cannot be readily replaced by the Company. They further agree that in the course of performing their services, the Executive will have
access to various types of proprietary information of the Company, which, if released to others or used by the Executive other than for
the benefit of the Company, in either case without the Company’s written consent, could cause the Company to suffer irreparable
injury. Therefore, the obligation of the Executive established under Section 6 and Section 7 hereof shall be enforceable both at law
and in equity, by injunction, specific performance, damages or other remedy; and the right of the Company to obtain any such remedy shall
be cumulative and not alternative and shall not be exhausted by any one or more uses thereof. Any adjudication against Executive by the
Company shall be in accordance with the laws of Massachusetts and Massachusetts employee rights.

 

	9.	MODIFICATION
                                            AND TERMINATION

 

	a.	Modification.
    The Agreement may be amended or modified only with the mutual written consent of the parties, and in its present form consists
    of the entire Agreement between and amongst the parties.
	 	 
	b.	Termination-General.
    The Agreement may be terminated by either party by giving 180 (one hundred and eighty) days’ notice to the other party,
    and by the Company upon the occurrence of any one of the following events: (a) the death of the Executive; (b) the occurrence to
    Executive of a physical or mental disability which, in the judgment (reasonably exercised) of the Chief Executive Officer, renders
    Executive unable to perform their normal duties on behalf of the Company for a continuous period of six (6) months (measured from
    the first day of the month immediately following the occurrence of such disability); or (c) a determination by the Chief Executive
    Officer that there is “Cause” (as described in section (d) below) to terminate Executive’s employment.
	 	 
	C.	By
    Death or Disability. In the event of the Executive’s death, their base compensation otherwise due for the succeeding
    period of time but no less than three (3) full calendar months following their death shall be paid to their designated beneficiary,
    or to their estate if no beneficiary has been designated. In the event of their disability the Executive shall be paid their compensation
    for the succeeding period of time but no less than three (3) months. Thereafter for the succeeding three (3) months shall be treated
    as being on an authorized unpaid leave of absence.
	 	 
	d.	For
    Cause. For purposes of the Agreement, the term “Cause” shall include, but not be limited to (i) the Executive’s
    willful misconduct or gross negligence; (ii) Executive’s conscious disregard of their obligations hereunder or of any other
    duties reasonably assigned by the Chief Executive Officer; (iii) Executive’s repeated conscious violation of any provision
    of the law, the Company’s By-Laws or of its other stated policies, standards, practices, regulations or procedures; (iv) Executive’s
    commission of any act involving moral turpitude; (v) a determination that Executive has demonstrated a dependence upon any addictive
    substance, including but not limited to alcohol, controlled substances, narcotics or barbiturates; or (vi) continued, willful and
    deliberate non-performance by the Executive of their duties hereunder (other than by reason of the Executive’s physical or
    mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance
    from the Chief Executive Officer.

 

    	5

    	 

    

 

	e.	Continued
    Effectiveness of Certain Obligations. No termination or expiration of the Agreement, whether consummated by action of either
    party or by operation of the terms hereof, shall relieve the Executive from their continued performance of the obligations established
    under Sections 6 and 7 hereof.
	 	 
	f.	Resignation
    as an Officer or Director. Immediately upon any termination of Executive’s employment for any reason, Executive shall
    be deemed to have resigned any position he may then hold as an officer of the Company or a member of the Board of Directors or similar
    body of any of Company’s affiliates, and as a fiduciary of any Company benefit plan.
	 	 
	g.	“Good
    Reason”. Executive shall be considered to have “Good Reason” to resign their position in the event of:
    (i) a material diminution in the Executive’s base compensation or Target Bonus below the amount as of the date of this Agreement
    or as increased during the course of their employment with the Company, excluding one or more reductions (totaling no more than 20%
    in the aggregate) generally applicable to all senior executives provided; (ii) a material diminution in the Executive’s authority,
    duties or responsibilities; or (iii) a material change in the geographic location at which the Executive must perform services.

 

If
Executive believes that they have “Good Reason” to resign their position, Executive must provide written notice of the occurrence
of the event constituting Good Reason and their desire to terminate their employment with the Company on account of such Good Reason
within thirty (30) days of the occurrence. Thereafter, Company will have a period of thirty (30) days following receipt of such written
notice to cure the condition. If the Company does not cure the event constituting Good Reason within such thirty (30) day period, the
Executive’s employment will terminate the day immediately following the end of such thirty (30) day period, unless the Company
provides for an earlier employment termination date.

 

	10.	CHANGE
                                            OF CONTROL

 

If
Executive’s termination of employment occurs within 3 months prior to or 12 months after a “Change in Control” as
defined in this section and such termination is either (a) by the Company without “Cause,” or (b) by Executive for
“Good Reason,” then: (i) Executive would be entitled to receive, in lieu of the severance amount described in Section 4,
a severance amount equal to the sum of their current base salary and target annual bonus for the then current fiscal year (or if
higher, the target annual bonus for the fiscal year immediately prior to the Change in Control), and (ii) Subject to the
Executive’s copayment of premium amounts at the active employees’ rate, the Executive may continue to participate in the
Company’s group health, dental and vision program for 12 months; provided, however, that the continuation of health benefits
under this Section shall reduce and count against the Executive’s rights under COBRA.

 

    	6

    	 

    

 

For
the purposed of this Agreement, a “Change in Control” shall mean the occurrence of any of the following events:

 

	a.	The
                                            approval by stockholders of the Company of:

	 	1.	Any
    consolidation or merger of the Company in which the company is not the continuing or surviving corporation, or
	 	2.	A
    sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all the
    assets of the Company to a party which is not controlled by the Company;

 

	b.	Either:

	 	1.	The
    receipt by the Company of a report on schedule 13D, or an amendment to such a report, filed with the Securities and Exchange Commission
    (“SEC”) pursuant to Section 13(d) of the Securities Exchange Act of 1934 (the “1934 Act”) disclosing that
    any person, group, corporation or other entity (a “Person”) has become the beneficial owner, directly or indirectly,
    of 30% or more of the outstanding stock of the Company, or
	 	2.	The
    actual knowledge by the Company of facts, on the basis of which any person is required to file such a report on schedule 13D, or
    an amendment to such a report, with the SEC (or would be required to file such a report or amendment upon the lapse of the applicable
    period of time specified in Section 13(d) of the 1934 Act) disclosing that such a person has become the beneficial owner, directly
    or indirectly, of 30% or more of the outstanding stock of the Company;

 

	c.	The
    purchase by any person (as defined in Section 13(d) of the 1934 Act), corporation or other entity, other than the Company or a wholly
    owned subsidiary or a parent company of the Company, of shares pursuant to a tender or exchange offer, to acquire any stock of the
    Company (or securities convertible into stock) for cash, securities or any other consideration provided that, after consummation
    of the offer, such person, group, corporation or other entity is the beneficial owner (as defined in rule 13d-3 under the 1934 Act),
    directly or indirectly, of 30% or more of the outstanding stock of the Company (calculated as provided in paragraph (d) of Rule 13d-3
    under the 1934 act in the case of rights to acquire stock); or
	 	 
	d.	The
    combination or merger of the Company with another company in which the Company is the surviving corporation but, immediately after
    the combination, the shareholders of the Company immediately prior to the combination do not hold, directly or indirectly, more than
    30% of the voting stock of the combined company (therefore being excluded from the number of shares held by such shareholders, but
    not from the voting stock of the combined company, any shares received by affiliates (as defined in the rules of the Securities and
    Exchange Commission) of such other company in exchange for stock of such other company).

 

	11.	INDEBTEDNESS
                                            OF EXECUTIVE

 

If,
during the course of their employment, Executive becomes indebted to the Company for any reason, the Company shall, if it so elects,
have the right to set off and to collect any sums due it from the Executive out of any amounts which it may owe to the
Executive for unpaid compensation. In the event that the Agreement terminates for any reason, all sums owed by the Executive to the
Company shall become immediately due and payable.

 

    	7

    	 

    

 

	12.	MISCELLANEOUS
                                            PROVISIONS

 

	a.	Non-assignment:
    Neither the Agreement nor any right or interest hereunder shall be assigned by the Executive or their legal representatives.
	 	 
	b.	Enforcement:
    If any term or condition or the Agreement shall be invalid or deemed unenforceable to any extent or in any application, then
    the remainder of the Agreement, and such terms or conditions except to such extent or in such application, shall not be affected
    thereby, and each and every term and condition of the Agreement shall be valid and enforced to the fullest extent and in the broadest
    application permitted by law.
	 	 
	C.	Notice:
    All notices or other communications required or permitted to be furnished pursuant to the Agreement shall be in writing and
    shall be considered as delivered when received by the recipient.
	 	 
	d.	Application
    of Massachusetts Law: The Agreement, and the application or interpretation thereof, shall be governed exclusively by its
    terms and by the laws of the State of Massachusetts. Venue shall be deemed located in Middlesex County, Massachusetts.
	 	 
	e.	Counterparts:
    The Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which
    together shall constitute on and the same instrument.
	 	 
	f.	Binding
    Effect: Each of the provisions and agreements herein contained shall be binding upon and inure to the benefit of the personal
    representatives, devisees, heirs, successors, transferees and assigns of the respective parties hereto.
	 	 
	g.	Cooperation:
    During and following the active life of this Agreement, Executive shall give Executive’s assistance and cooperation
    willingly, upon reasonable notice (which shall include due regard to the extent reasonably feasible for Executive’s employment
    obligations and prior commitments), in any matter relating to Executive’s position with the Company or Executive’s knowledge
    as a result thereof as the company may reasonably request, including Executive’s attendance and truthful testimony where deemed
    appropriate by the Company, with respect to any investigation or the Company’s defense or prosecution of any existing or future
    claims or litigations or other proceeding relating to matters in which he was involved or had knowledge by virtue of Executive’s
    employment with the Company. The Company will reimburse Executive for reasonable out-of-pocket travel costs and expenses incurred
    by Executive (in accordance with Company policy) as a result of providing such assistance.
	 	 
	h.	Legal
    Fees and Costs: If a legal action is initiated by any party to the Agreement against another, arising out of or relating
    to the alleged performance or non-performance of any right or obligation established hereunder, or any dispute concerning the same,
    any and all fees, costs and expenses reasonably incurred by each successful party in investigating, preparing for, prosecuting, defending
    against, or providing evidence, producing documents or taking any other action in respect of, such action shall be the joint and
    several obligation of and shall be paid or reimbursed by the unsuccessful party.
	 	 
	i.	Indemnification:
    The Company hereby agrees to indemnify Executive and hold Executive harmless to the fullest extent permitted by law and under
    the bylaws of the Company against and in respect to any and all actions, suits, proceedings, claims, demands, judgements, costs,
    expenses (including reasonable attorney’s fees), losses, and damages resulting from Executive’s good faith performance
    of their duties and obligations with the Company, except in the case of gross negligence or willful misconduct, whether or not such
    claims, demands, judgements, costs, expenses, losses, and damages are asserted or filed during the active life of this Agreement.
	 	 
	j.	Survival:
    The Parties’ obligations under Sections 6, 7, 8, 10, 11, and 12 shall survive the Termination of this agreement.

 

[Remainder
of page intentionally left blank; Signature page follows]

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed the Agreement,

 

	COMPANY	 
	 	 
	/s/
                                            Erica Monaco
	 
	Erica
    Monaco; CEO	 
	Biofrontera
    Inc.	 
	 	 
	10/3/2022	 
	Date	 
	 	 
	EXECUTIVE	 
	 	 
	/s/
    Fred Leffler	 
	Fred
    Leffler	 
	 	 
	10/3/2022	 
	Date	 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]